Anxiety Medications —
Every Class Compared

Sertraline is the most commonly prescribed SSRI in the world and is frequently the first choice for anxiety disorders. It holds FDA approval for panic disorder, social anxiety disorder, PTSD, and OCD — the broadest anxiety-related approval set of any SSRI. It is well studied, widely available as a generic, and has a long safety record.

Like all SSRIs, sertraline takes 2–6 weeks to produce its full anxiety-reducing effect. This delay can be difficult early in treatment, particularly for patients in acute distress. Some prescribers briefly add a short-acting medication during this window while the SSRI takes effect. Common early side effects include nausea and GI upset, which usually improve over the first few weeks.

Available as 25mg, 50mg, and 100mg tablets, and as an oral concentrate solution.

Escitalopram is the most chemically selective SSRI — it works on the serotonin transporter with minimal activity at other receptors, which translates to a cleaner side effect profile for many patients. It holds FDA approval specifically for generalized anxiety disorder (GAD) and major depressive disorder.

Its minimal effect on liver enzymes (cytochrome P450) makes it one of the better choices for patients already taking multiple medications. Like all SSRIs, it requires consistent daily use for several weeks before full benefits emerge. Available in 5mg, 10mg, and 20mg tablets, and as an oral solution.

Paroxetine has the most FDA-approved anxiety indications of any SSRI, covering social anxiety disorder, panic disorder, GAD, PTSD, and OCD. It is particularly well studied in social anxiety disorder, where it remains a first-line option.

Paroxetine is the most anticholinergic SSRI and has the shortest effective half-life among SSRIs — both factors that make stopping or skipping doses more noticeable. It is a strong inhibitor of the CYP2D6 enzyme, meaning it interacts with many other medications. Any taper should be gradual and guided by a prescriber. Available in 10mg, 20mg, 30mg, and 40mg tablets, and a controlled-release (CR) formulation.

Fluoxetine is the oldest FDA-approved SSRI (1987) and holds approval for panic disorder and OCD among its anxiety-related indications. Its most clinically notable characteristic is its extremely long half-life — the parent drug and its active metabolite (norfluoxetine) remain active for days to weeks after the last dose.

This long half-life makes fluoxetine uniquely forgiving of missed doses and dramatically reduces the risk of discontinuation syndrome — the drug effectively tapers itself. Fluoxetine tends to be activating rather than sedating, which can be helpful for patients with fatigue but may temporarily worsen anxiety early in treatment. Available in 10mg, 20mg, and 40mg capsules/tablets.

Venlafaxine (Effexor XR) is an SNRI — it blocks the reuptake of both serotonin and norepinephrine. It holds FDA approval for GAD, social anxiety disorder, and panic disorder, making it one of the most comprehensively approved medications for anxiety. In clinical practice, it is often considered alongside SSRIs as a first-line option for anxiety disorders.

Because it affects both serotonin and norepinephrine, venlafaxine may be particularly useful when anxiety occurs alongside chronic pain or fatigue, or when a patient has not responded adequately to an SSRI. At higher strengths (prescribed by your doctor), the norepinephrine effect becomes more prominent.

Venlafaxine has a relatively short half-life, and abrupt discontinuation can produce pronounced discontinuation symptoms. It should always be tapered slowly under prescriber supervision. Available in extended-release (XR) capsules.

Duloxetine is an SNRI with FDA approval for GAD, making it one of a handful of medications specifically approved for that indication. It has the added benefit of approval for several chronic pain conditions — fibromyalgia, diabetic peripheral neuropathy, and musculoskeletal pain — which makes it a practical choice when anxiety co-occurs with physical pain.

Like venlafaxine, duloxetine takes several weeks to reach its full effect. It is metabolized through the liver (CYP1A2 and CYP2D6), so prescribers review other medications before starting it. Available in delayed-release capsules in multiple strengths.

Alprazolam is one of the most prescribed medications in the United States and one of the fastest-acting benzodiazepines for anxiety. It works by enhancing the activity of GABA — the brain's main inhibitory neurotransmitter — producing rapid sedation and anxiety relief, typically within 15–30 minutes of a dose.

Alprazolam holds FDA approval for panic disorder and generalized anxiety disorder. However, because it is shorter-acting than some other benzodiazepines, effects wear off relatively quickly — which can contribute to rebound anxiety between doses and a higher perceived need for repeated use. This pharmacology makes dependence develop more quickly with regular use than with longer-acting agents like clonazepam.

Available in 0.25mg, 0.5mg, 1mg, and 2mg immediate-release tablets; extended-release (XR) tablets in multiple strengths; and oral concentrate.

Lorazepam is an intermediate-acting benzodiazepine widely used for acute anxiety, procedural anxiety, and short-term management while longer-term treatments are being established. It does not produce significant active metabolites, which makes its effects more predictable and is why it is often preferred for older adults or patients with liver concerns compared to longer-acting benzodiazepines like diazepam.

Lorazepam is also available in injectable form, making it a common choice in emergency or hospital settings. For outpatient anxiety management, oral tablets are available in 0.5mg, 1mg, and 2mg strengths. Like all benzodiazepines, regular use carries dependence risk.

Clonazepam is a longer-acting benzodiazepine that holds FDA approval for panic disorder. Its longer half-life (18–50 hours) compared to alprazolam means effects last longer and blood levels are more stable with twice-daily dosing — some clinicians consider this a practical advantage when bridging to SSRI therapy, as rebound anxiety between doses is less pronounced.

The longer half-life also means that when a taper is eventually needed, it can be easier to manage than with shorter-acting agents. However, dependence risk is comparable to other benzodiazepines. Available in 0.5mg, 1mg, and 2mg tablets, as well as orally disintegrating wafers.

Diazepam is one of the original benzodiazepines, introduced in 1963. It has an extremely long half-life (20–100 hours) and produces several active metabolites that can persist in the body for days. This long duration makes it more forgiving of missed doses but also means that effects — and side effects including sedation — can accumulate with repeated use, particularly in older adults.

Diazepam is FDA-approved for anxiety disorders, alcohol withdrawal, muscle spasm, and as a seizure rescue medication. For anxiety specifically, it is less commonly used as a primary long-term agent today, but remains available for acute episodes. Available in 2mg, 5mg, and 10mg tablets; oral solution; and injectable formulation.

Buspirone is a unique anxiolytic that works through a completely different mechanism than benzodiazepines — it is a partial agonist at the 5-HT1A serotonin receptor and has some dopamine receptor activity. It does not cause sedation, does not impair cognitive function, and carries no physical dependence risk. It is FDA-approved specifically for GAD.

The tradeoff for these advantages is that buspirone requires consistent daily use for 2–4 weeks before its anxiety-reducing effects become apparent. It does not provide any immediate relief and is not useful on an as-needed basis. Patients transitioning from benzodiazepines may not find it subjectively satisfying at first, since it produces no noticeable sedative effect.

Buspirone is often considered when a patient needs long-term GAD management without the risks associated with benzodiazepines, or when sedation would be problematic. Available in 5mg, 10mg, 15mg, and 30mg tablets.

Propranolol is a beta blocker — a medication primarily developed for cardiovascular conditions (hypertension, heart rhythm disorders) that blocks adrenaline receptors throughout the body. Its off-label use for performance anxiety is widespread and supported by decades of clinical practice. Musicians, public speakers, surgeons, and others use it situationally to control the physical symptoms of anxiety: heart racing, trembling hands, sweating, and voice shakiness.

Propranolol does not reduce the psychological experience of anxiety — it targets the peripheral physical symptoms driven by the sympathetic nervous system. It is taken on an as-needed basis (typically 30–60 minutes before the anxiety-provoking event) rather than daily. It is not appropriate for GAD, social anxiety as a primary disorder, or panic disorder.

Propranolol is not recommended in patients with certain conditions including asthma, COPD, or certain heart conditions. Available in immediate-release tablets and extended-release capsules (Inderal LA).

Hydroxyzine is an antihistamine that, at the doses prescribed for anxiety, produces notable sedation and anxiolytic effects. It works through H1 histamine receptor blockade and some serotonin receptor activity. It is FDA-approved for anxiety and tension, and is widely used as a non-habit-forming alternative to benzodiazepines for acute anxiety.

Because hydroxyzine causes sedation, it is particularly useful for patients whose anxiety is accompanied by difficulty sleeping, or for situational anxiety where some sedation is acceptable. Unlike benzodiazepines, it carries no dependence risk and is not a controlled substance, which makes it a first choice in many settings where benzodiazepines are contraindicated or undesirable.

Side effects include drowsiness, dry mouth, and blurred vision. Available as hydroxyzine pamoate (Vistaril) capsules and hydroxyzine hydrochloride (Atarax) tablets, in multiple strengths.

Pregabalin is a gabapentinoid — a medication that modulates calcium channels in neurons by binding to the alpha-2-delta subunit, reducing excitatory neurotransmitter release. It is approved for GAD in Europe and several other countries, where it is considered a first-line option. In the United States, it holds approval for neuropathic pain conditions and fibromyalgia, but is used off-label for anxiety.

Pregabalin acts somewhat faster than SSRIs for anxiety — effects may be noticed within days to a week — and clinical trials have demonstrated efficacy for GAD comparable to established treatments. It also helps with sleep disturbance associated with anxiety.

Pregabalin is a Schedule V controlled substance in the US due to some misuse potential (it can produce euphoria at high doses). Side effects include dizziness, sedation, and weight gain. Available in capsules and oral solution in multiple strengths.

Gabapentin is a gabapentinoid closely related to pregabalin, originally developed as an anticonvulsant and approved for certain seizure types and postherpetic neuralgia. Its use for anxiety is entirely off-label in the United States, but it is commonly prescribed for anxiety — particularly in patients who are being tapered off benzodiazepines or who have a history of substance use that makes scheduled medications less appropriate.

Clinical evidence for gabapentin in anxiety is more limited than for SSRIs or pregabalin, but real-world use is substantial, especially for social anxiety disorder and in benzo-dependent patients where it may ease the transition. It produces some sedation, which can be helpful when anxiety disrupts sleep.

Gabapentin is not federally scheduled but several states have added it to their controlled substance lists due to growing recognition of misuse potential. Available in capsules, tablets, and oral solution in multiple strengths.